Burford Brothers Inc. Sells 8,183 Shares of Johnson & Johnson $JNJ

Burford Brothers Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 47.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,979 shares of the company’s stock after selling 8,183 shares during the quarter. Burford Brothers Inc.’s holdings in Johnson & Johnson were worth $1,372,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. GFG Capital LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $35,000. Stone House Investment Management LLC purchased a new position in Johnson & Johnson in the 1st quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the 1st quarter valued at $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the first quarter worth $52,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Stifel Nicolaus increased their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday. Citigroup increased their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Bank of America increased their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Finally, Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $199.88.

Johnson & Johnson Trading Up 0.6%

Shares of JNJ opened at $193.27 on Monday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40. The company has a market capitalization of $465.45 billion, a P/E ratio of 18.65, a P/E/G ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm’s 50 day simple moving average is $180.49 and its 200 day simple moving average is $164.90.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is 50.19%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.